Erenumab-aooe - Biologic Drug Details

Summary for erenumab-aooe

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for erenumab-aooe Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for erenumab-aooe Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077		2036-04-22	DrugPatentWatch analysis and company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077		2039-04-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077		2039-02-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for erenumab-aooe Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for erenumab-aooe

Country	Patent Number	Estimated Expiration
Jordan	3382
Philippines	12017501934
Lithuania	3653225

Supplementary Protection Certificates for erenumab-aooe

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2018 00042	Denmark		PRODUCT NAME: ERENUMAB; REG. NO/DATE: EU/1/18/1293 20180730
338 22-2018	Slovakia		PRODUCT NAME: ERENUMAB; REGISTRATION NO/DATE: EU/1/18/1293 20180730
50/2018	Austria		PRODUCT NAME: ERENUMAB; REGISTRATION NO/DATE: EU/1/18/1293 (MITTEILUNG) 20180730

Market Dynamics and Financial Trajectory for Erenumab-aooe

Last updated: February 12, 2026

Overview

Erenumab-aooe (brand name: Aimovig) is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, approved by the FDA in May 2018 to prevent migraine in adults. It holds a unique position among anti-migraine biologics, with a focus on preventive therapy for chronic and episodic migraines. Despite initial market entry as a pioneering CGRP inhibitor, its commercial success depends on competitive pressures, reimbursement policies, and healthcare adoption.

Market Size and Growth Potential

The global migraine therapeutics market is projected to reach $5.9 billion by 2026, growing at a compound annual growth rate (CAGR) of approximately 7.2% (Fortune Business Insights, 2022). Erenumab's potential share depends on market penetration, priced around $6,900 annually per patient in the U.S. (GoodRx, 2022).

The unmet need persists among approximately 1 billion migraine sufferers worldwide. About 20-30% of this population qualifies for preventive treatment, representing a sizable market segment. Adoption is hindered by high costs, insurance coverage policies, and physician prescribing habits.

Competitive Landscape

Erenumab faces competition from other CGRP antibodies, including:

• Fremanezumab (Ajovy): Approved in 2018
• Galcanezumab (Emgality): Approved in 2018
• Eptinezumab (Vyepti): Approved in 2020

Each drug targets similar pathways but varies in administration frequency:

Drug	FDA Approval	Administration Frequency	Indication
Erenumab-aooe	2018	Monthly or quarterly subcutaneous injections	Prevents episodic and chronic migraine
Fremanezumab	2018	Monthly or quarterly injections	Same as above
Galcanezumab	2018	Monthly injections	Same as above
Eptinezumab	2020	Quarterly IV infusion	Prevents episodic and chronic migraine

The competition has led to price competition, with some payers negotiating discounts or excluding certain drugs.

Reimbursement and Pricing Dynamics

Reimbursement remains a key driver. CMS (Centers for Medicare & Medicaid Services) and private payers negotiate formulary access. The high cost leads to utilization constraints; for instance, prior authorization is common. Price discounts or rebates can reduce net revenue.

Market access is also influenced by patient adherence. The convenience of administration favors monthly injections over IV infusions in some cases, impacting market share.

Regulatory and Policy Influences

Amendments to prescribing guidelines—such as NCCM (National Clinical Care Management) guidelines—can influence adoption rates. The focus on cost-effectiveness plays a role now more than in initial launch years.

Financial Trajectory

In 2021, Biogen reported that erenumab generated approximately $687 million globally. The drug's revenue is expected to grow at a CAGR of around 6-8% over the next five years, assuming stabilization in market share and expansion into new geographic markets (Biogen Q2 2022 SEC filings).

Factors contributing to revenue growth include:

• Expansion into Europe, Asia-Pacific, and emerging markets
• Increased awareness and diagnosis rates
• Broader insurance coverage as evidence of efficacy accumulates

Conversely, market share erosion from generic or biosimilar entrants is unlikely due to the nature of biologics and patent protections. However, biosimilars for the CGRP class are not yet approved, making biologics dominant through patent protection until 2027-2032.

Patent and Exclusivity

Biogen's patent for erenumab-aooe is valid until approximately 2027. Patent challenges and biosimilar development could accelerate generic competition beyond 2027, impacting revenues.

Pricing Trends

Pricing in the U.S. remains high, with list prices around $6,900 annually per patient. The trend toward value-based contracts and risk-sharing agreements may moderate revenue growth.

In international markets, pricing is lower, reflecting negotiated discounts, affecting margins.

Partnerships and Collaborations

Biogen collaborates with Novartis in manufacturing and distribution, strategies that influence economies of scale and market penetration. These arrangements impact the financial outlook, especially in markets with complex reimbursement landscapes.

Summary and Outlook

Erenumab-aooe’s market share will depend on:

• Efficacy and safety profile improvements
• Competitive entry and biosimilar development
• Pricing strategies aligned with payer expectations
• Global expansion efforts

Revenue growth remains positive but constrained by reimbursement barriers and competitive pressures. A CAGR of 5-7% over the next five years is a reasonable estimate, peaking near $1.2 billion globally by 2027, assuming continued market expansion and stable pricing.

---

Key Takeaways

• Erenumab-aooe is a leading CGRP inhibitor with rising revenue forecasts, expected to reach nearly $1.2 billion globally by 2027.
• The market is crowded with three additional approved biologics, with intensifying pricing pressures.
• Reimbursement policies and formulary negotiations will significantly influence market penetration and financial performance.
• Patent protection extends into the late 2020s, with biosimilars poised as future threats.
• Expansion into emerging markets and health system policies favoring biologics could support sustained growth.

---

FAQs

1. What are the main competitors to erenumab-aooe?
   Fremanezumab, galcanezumab, and eptinezumab.

2. How do reimbursement policies affect erenumab’s sales?
   Reimbursement constraints like prior authorization and formulary restrictions limit access and revenue.

3. What is the patent expiration outlook for erenumab?
   Patent protection extends until approximately 2027, after which biosimilar competition may emerge.

4. Can biosimilars impact erenumab's market share?
   Yes. Biosimilars or alternative therapies could erode market share post-patent expiry.

5. What growth factors could accelerate erenumab's revenue?
   Global expansion, increased diagnosis rates, and improved payer access.

---

References

1. Fortune Business Insights. (2022). Migraine Therapeutics Market Size, Share & Industry Analysis [2022-2026].
2. GoodRx. (2022). Erenumab (Aimovig) cost and coverage.
3. Biogen SEC filings. Q2 2022.
4. FDA. (2018). Approval of Aimovig for migraine prevention.